AI product management · Industry brief

On July 7, 2026, the FTC published a proposed policy statement targeting AI companies that steer system outputs contrary to consumer expectations without disclosure, including modifications made to comply with state AI laws like Colorado's revised Artificial Intelligence Act. The FTC declared such undisclosed conduct violates Section 5 of the FTC Act as deception, applying its longstanding data privacy enforcement framework to AI systems. The policy covers foundation model developers, application builders, and enterprise users making AI capability representations, with a disclosure safe harbor requiring "clear and conspicuous" prominence rather than fine-print disclaimers. Companies face potential liability for deliberate accuracy suppression whether motivated by profit, ideology, or state law compliance, though technological limitations and balancing accuracy with other user-aligned objectives are carved out. The FTC's approach signals implied federal preemption over conflicting state AI laws, creating a compliance dilemma for companies operating in Colorado and similar jurisdictions: modifying outputs to comply with state law may trigger federal deception liability, while prioritizing accuracy may trigger state liability. The agency recommends companies audit for undisclosed output steering, review marketing representations, evaluate state-law compliance measures, develop robust disclosure strategies, document design decisions, and file comments by July 31, 2026 (FTC Docket FTC-2026-0859). Given the FTC's historical track record of enforcing positions signaled through policy statements, this proposal is treated as a strong indicator of enforcement priorities. Source: Federal Trade Commission policy statement (91 Fed. Reg. 128, page 41638).

A July 2026 Nature Medicine framework paper exposed significant gaps in FDA's regulatory benchmarking infrastructure for clinical AI systems. The paper highlights a structural problem: large language models score ~92% on standardized medical exams but only 44.8% on real-world clinical tasks using the BRIDGE benchmark, revealing that current FDA guidance lacks task-specific performance standards. FDA's January 2025 draft guidance on AI supporting regulatory decisions establishes general principles around transparency and human oversight but does not define acceptable benchmarks for specific clinical applications like automated safety signal detection or AI-assisted eligibility screening in trials. An April 2026 FDA warning letter to Purolea Cosmetics Lab established enforcement precedent that AI-generated outputs require documented human validation before informing regulated decisions, a principle directly applicable to trial design contexts. Sponsors deploying AI tools for protocol design, adaptive randomization, and safety monitoring currently operate without defined validation standards, creating material regulatory risk for platform vendors whose products perform well on academic benchmarks but lack task-specific clinical validation. The clinical trial protocol design AI market reached USD 1.37 billion in 2024, with significant vendor commitments made absent regulatory clarity. FDA's finalization of its January 2025 draft guidance is the key regulatory artifact to watch, as it will retroactively define whether currently deployed AI-assisted trial tools meet standards.

Colorado passed Senate Bill 26-189 in May 2026, repealing and replacing its original 2024 Colorado AI Act. The revised law, effective January 1, 2027, narrows the regulatory scope from broad "high-risk AI systems" to automated decision-making technology (ADMT) used to materially influence consequential decisions in employment, lending, housing, and healthcare. The new framework eliminates requirements for algorithmic discrimination governance, risk management programs, and annual impact assessments, significantly reducing documentation burdens. However, compliance obligations remain concentrated on transparency, documentation, and consumer rights—developers must provide technical information about intended uses, training data, limitations, and foreseeable risks, while deployers must provide pre-use notices, post-decision disclosures, and mechanisms for consumers to request information, correct data, and obtain human review. The law reflects a broader US regulatory trend toward transparency and consumer rights in automated decision-making, with similar frameworks emerging in Connecticut and California.

Pharmaceutical companies are implementing self-governance frameworks for AI in Canada as regulatory development lags behind rapid AI adoption in the sector. At the PCC Canada Pharma & MedTech Compliance conference, compliance leaders from Boehringer Ingelheim, Amgen, and AstraZeneca discussed that 74% of delegates use AI tools daily with over 80% planning increased AI investment in compliance activities. Data privacy and security emerged as the primary concern among 90% of professionals polled, alongside risks including AI hallucinations, governance gaps, and data validity issues. Canada currently lacks comprehensive AI-specific legislation following Bill C-27's failure in 2025, leaving organizations to navigate fragmented regulations under PIPEDA, Competition Bureau guidance, and Health Canada rules for medical devices. The panelists outlined four governance principles: hands-on review between business and compliance, integration with existing processes like privacy impact assessments, principles-based approaches emphasizing transparency and accountability, and enabling employee-led innovation. Compliance leaders emphasized that self-regulation serves as the most effective interim approach while a new national AI strategy is being drafted for 2026, positioning AI governance as an enhancement to existing compliance frameworks rather than standalone oversight structures.